The Effects of Natural Versus Man-Made Trans Fatty Acids on Lipoprotein Profiles: A Pilot Study

NCT ID: NCT00535886

Last Updated: 2008-05-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-11-30

Study Completion Date

2006-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test the effects of natural vs. man-made trans fatty acids (trans fats) on blood cholesterol.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Since the purpose of the study is to determine the statistical power required for a definitive study testing and comparing the effects of two trans fatty acids, vaccenic and elaidic acid, on lipoprotein profiles, no hypotheses will be specified.

Specific Aims:

1. To determine the variability in the lipid and lipoprotein response to diets enriched in natural versus man-made trans fats in order to appropriately power a larger scale clinical study
2. To optimize the delivery of trans fat-enriched diets through the development of supplemental food items

The adverse health effects of trans fatty acids (TFA) on cardiovascular disease (CVD) risk have been established in a number of metabolic and epidemiological studies \[Willett 1993, Hu 1997, Ascherio 1996, Pietinen 1997, Oomen 2001\]. Trans fats are fatty acids with 18 carbon chains and one or more double bond(s). The hydrogen atoms of the double bond(s) are in a configuration (trans rather than cis) that results in the straightening of a normally kinked unsaturated fatty acid chain. Trans fats occur naturally in low quantities in dairy and beef products, but have also been artificially introduced to the food supply by the process of the hydrogenation of vegetable oils \[Mann 1994\]. Only two studies linking the consumption of trans fatty acids with an increased risk of CVD have distinguished between the effects of man-made versus naturally occurring trans fatty acids \[Willett 1993, Oomen 2001\].

It has been suggested that the relationship between trans fatty acids and coronary heart disease is specifically attributable to man-made trans fatty acids. In fact, some of the trans fats that occur naturally in animal products, in particular, conjugated linoleic acid (CLA), may have beneficial health effects. CLA has been shown to be anti-carcinogenic \[Ip 2003\], anti-atherogenic \[McLeod 2004\] and anti-diabetic \[Rainer 2004\]; it has also been shown to enhance the immune response and have positive effects on growth and energy partitioning. As a precursor to CLA, vaccenic acid (VA), another trans fatty acid found in dairy and beef products, may also provide health benefits. Bioconversion of VA to CLA has been recently demonstrated \[Turpeinen 2002\]. The effects of diet supplementation with VA on health parameters have yet to be defined.

The objective of the overall research project will be to test the hypothesis that the ingestion of high doses of naturally occurring VA does not cause the adverse lipid and lipoprotein effects known to occur with the consumption of man made trans fatty acids, in particular, elaidic acid (EA). The latter is the primary trans fatty acid found in products such as margarines, cakes, cookies, crackers and other baked and processed foods \[Steinhart 2003\]. The primary outcome measure will be the ratio of total to high density lipoprotein (HDL) cholesterol. Related secondary outcome measures include concentrations of low density lipoprotein (LDL) cholesterol, HDL cholesterol, triglyceride (TG) and Lp(a). The present proposal is designed to test the feasibility of, and determine the power for, a definitive study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Disease Diabetes Dyslipidemia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Trans Fatty Acids conjugated linoleic acid vaccenic acid High Density Lipoprotein Cholesterol Low Density Lipoprotein Cholesterol Beef

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Elaidic Acid

Group Type ACTIVE_COMPARATOR

Man-made Trans FA

Intervention Type DIETARY_SUPPLEMENT

EA as 6% of total energy

Vaccenic Acid

Group Type EXPERIMENTAL

Natural Trans FA

Intervention Type DIETARY_SUPPLEMENT

VA as 6% of total energy

Oleic Acid

Group Type PLACEBO_COMPARATOR

Oleic Acid

Intervention Type DIETARY_SUPPLEMENT

OA as 6% of total energy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Man-made Trans FA

EA as 6% of total energy

Intervention Type DIETARY_SUPPLEMENT

Natural Trans FA

VA as 6% of total energy

Intervention Type DIETARY_SUPPLEMENT

Oleic Acid

OA as 6% of total energy

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male
* Age \>= 18 years
* Body mass index (BMI) less than 35 kg/m\*m
* Fasting total cholesterol and LDL cholesterol less than the 95% for age and sex
* Fasting triglyceride \<= 400 mg/dl
* Fasting blood glucose \<= 125 mg/dl
* Fasting thyroid stimulating hormone less than 0.3 or greater than 5.0 uIU/ml
* Blood pressure \<= 150/90
* Agrees to no alcohol during the study
* Agrees to maintain same level of physical activity throughout the study

Exclusion Criteria

* Smokers
* Personal history of coronary heart disease, cerebrovascular disease or vascular disease, diabetes, bleeding disorder, liver or renal disease, or of cancer (other than skin cancer) in the last five years.
* Use of drugs known to affect lipid metabolism, blood thinning agents, or hormones.
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cattlemen's Beef Association

INDUSTRY

Sponsor Role collaborator

UCSF Benioff Children's Hospital Oakland

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ronald M Krauss, M.D.

Role: PRINCIPAL_INVESTIGATOR

UCSF Benioff Children's Hospital Oakland

Patty Siri, Ph.D.

Role: STUDY_DIRECTOR

UCSF Benioff Children's Hospital Oakland

Shira Miller, M.D.

Role: STUDY_DIRECTOR

National Cattlemen's Beef Association

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Children's Hospital Oakland Research Institute

Oakland, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Willett WC, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Rosner BA, Sampson LA, Hennekens CH. Intake of trans fatty acids and risk of coronary heart disease among women. Lancet. 1993 Mar 6;341(8845):581-5. doi: 10.1016/0140-6736(93)90350-p.

Reference Type BACKGROUND
PMID: 8094827 (View on PubMed)

Hu FB, Stampfer MJ, Manson JE, Rimm E, Colditz GA, Rosner BA, Hennekens CH, Willett WC. Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med. 1997 Nov 20;337(21):1491-9. doi: 10.1056/NEJM199711203372102.

Reference Type BACKGROUND
PMID: 9366580 (View on PubMed)

Ascherio A, Rimm EB, Giovannucci EL, Spiegelman D, Stampfer M, Willett WC. Dietary fat and risk of coronary heart disease in men: cohort follow up study in the United States. BMJ. 1996 Jul 13;313(7049):84-90. doi: 10.1136/bmj.313.7049.84.

Reference Type BACKGROUND
PMID: 8688759 (View on PubMed)

Pietinen P, Ascherio A, Korhonen P, Hartman AM, Willett WC, Albanes D, Virtamo J. Intake of fatty acids and risk of coronary heart disease in a cohort of Finnish men. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Epidemiol. 1997 May 15;145(10):876-87. doi: 10.1093/oxfordjournals.aje.a009047.

Reference Type BACKGROUND
PMID: 9149659 (View on PubMed)

Oomen CM, Ocke MC, Feskens EJ, van Erp-Baart MA, Kok FJ, Kromhout D. Association between trans fatty acid intake and 10-year risk of coronary heart disease in the Zutphen Elderly Study: a prospective population-based study. Lancet. 2001 Mar 10;357(9258):746-51. doi: 10.1016/s0140-6736(00)04166-0.

Reference Type BACKGROUND
PMID: 11253967 (View on PubMed)

Mann GV. Metabolic consequences of dietary trans fatty acids. Lancet. 1994 May 21;343(8908):1268-71. doi: 10.1016/s0140-6736(94)92157-1.

Reference Type BACKGROUND
PMID: 7910281 (View on PubMed)

Ip MM, Masso-Welch PA, Ip C. Prevention of mammary cancer with conjugated linoleic acid: role of the stroma and the epithelium. J Mammary Gland Biol Neoplasia. 2003 Jan;8(1):103-18. doi: 10.1023/a:1025739506536.

Reference Type BACKGROUND
PMID: 14587866 (View on PubMed)

McLeod RS, LeBlanc AM, Langille MA, Mitchell PL, Currie DL. Conjugated linoleic acids, atherosclerosis, and hepatic very-low-density lipoprotein metabolism. Am J Clin Nutr. 2004 Jun;79(6 Suppl):1169S-1174S. doi: 10.1093/ajcn/79.6.1169S.

Reference Type BACKGROUND
PMID: 15159253 (View on PubMed)

Rainer L, Heiss CJ. Conjugated linoleic acid: health implications and effects on body composition. J Am Diet Assoc. 2004 Jun;104(6):963-8, quiz 1032. doi: 10.1016/j.jada.2004.03.016.

Reference Type BACKGROUND
PMID: 15175596 (View on PubMed)

Turpeinen AM, Mutanen M, Aro A, Salminen I, Basu S, Palmquist DL, Griinari JM. Bioconversion of vaccenic acid to conjugated linoleic acid in humans. Am J Clin Nutr. 2002 Sep;76(3):504-10. doi: 10.1093/ajcn/76.3.504.

Reference Type BACKGROUND
PMID: 12197992 (View on PubMed)

Steinhart H, Rickert R, Winkler K. Trans fatty acids (TFA): analysis, occurrence, intake and clinical relevance. Eur J Med Res. 2003 Aug 20;8(8):358-62.

Reference Type BACKGROUND
PMID: 12915330 (View on PubMed)

Griinari JM, Corl BA, Lacy SH, Chouinard PY, Nurmela KV, Bauman DE. Conjugated linoleic acid is synthesized endogenously in lactating dairy cows by Delta(9)-desaturase. J Nutr. 2000 Sep;130(9):2285-91. doi: 10.1093/jn/130.9.2285.

Reference Type BACKGROUND
PMID: 10958825 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB# 2005-45

Identifier Type: -

Identifier Source: secondary_id

MM6222

Identifier Type: -

Identifier Source: org_study_id